• Arcutis Biotherapeutics granted director Robert A. Scott 2,819 common shares on Oct. 23, 2026.
• Scott also received stock options covering 20,507 shares and 8,663 shares, each with a $31.2 exercise price.
• Both option awards expire Oct. 23, 2036.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-067898), on October 28, 2026, and is solely responsible for the information contained therein.